EXAS · As filed with the SEC

Exact Sciences income statement, by quarter

The statement as Exact Sciences presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.

Consolidated Statements of Operations · USD thousands, except per-share amounts; shares in thousands

USD thousands, except per-share amounts; shares in thousandsQ4 2025†
3 months ended Dec 31, 2025
Q3 2025
3 months ended Sep 30, 2025
Q2 2025
3 months ended Jun 30, 2025
Q1 2025
3 months ended Mar 31, 2025
Net loss(85,955)†(19,594)(1,185)(101,215)
Net loss before tax(85,083)†(17,757)(57)(100,991)
Loss from operations(82,595)†(25,545)(2,148)(96,010)
Gross profit615,826†583,929562,453500,547
Revenue—850,739811,085706,785
Cost of sales262,555†266,810248,632206,238
Total operating expenses698,421†609,474564,601596,557
Research and development191,495†117,290108,901105,310
Sales and marketing288,527†250,228247,118264,310
General and administrative217,993†241,413208,582220,686
Impairment of long-lived and indefinite-lived assets406†54306,251
Other operating income0†000
Total other income (expense)(2,488)†7,7882,091(4,981)
Investment income, net7,271†17,57711,9264,997
Interest Expense, Nonoperating(9,759)†(9,789)(9,835)(9,978)
Income Tax Expense (Benefit)(872)†(1,837)(1,128)(224)
Increase (decrease) in net loss per share (in usd per share)—(0.10)(0.01)(0.54)
Increase (decrease) in net loss per share (in usd per share)—(0.10)(0.01)(0.54)
Weighted average number of shares outstanding, basic (in shares)—189,262188,902186,813
Weighted average number of shares outstanding, diluted (in shares)—189,262188,902186,813

† Derived: worked out from the filings, not stated in them. A fourth quarter is the 10-K year less the nine months in the third-quarter 10-Q; a quarter of cash flows is year to date less the prior year to date.

As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.